XML 15 R4.htm IDEA: XBRL DOCUMENT v3.19.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2019
USD ($)
$ / shares
shares
Jun. 30, 2018
USD ($)
$ / shares
shares
Jun. 30, 2019
USD ($)
$ / shares
shares
Jun. 30, 2018
USD ($)
$ / shares
shares
Revenue, net of contractual allowances and adjustments $ 1,199 $ 959 $ 2,116 $ 1,755
less allowance for doubtful accounts (257) (142) (461) (226)
Net sales 942 817 1,655 1,529
Total cost of sales 770 642 1,445 1,330
Gross profit 172 175 210 199
OPERATING EXPENSES:        
Operating expenses 2,467 2,358 4,564 4,536
Impairment of goodwill       294
TOTAL OPERATING EXPENSES 2,467 2,358 4,564 4,830
OPERATING LOSS (2,295) (2,183) (4,354) (4,631)
OTHER INCOME (EXPENSE):        
Interest expense, net (178) (48) (201) (56)
Warrant revaluation (822) 323 (582) 584
Loss on modification of warrants (1,128)   (1,128)  
Derivative revaluation (438) (1) (415) (1)
Gain on settlement of liability, net 1,084 6 1,251 147
Loss on litigation (266)   (266)  
Loss on issuance of convertible notes (1,870) (928) (1,870) (928)
Loss on settlement of equity instruments       (385)
Other Income (Expense) (3,618) (648) (3,211) (639)
LOSS BEFORE INCOME TAXES (5,913) (2,831) (7,565) (5,270)
NET LOSS (5,913) (2,831) (7,565) (5,270)
Deemed dividends related to beneficial conversion feature of preferred stock and fair value of consideration issued to induce conversion of preferred stock   (334)   (3,848)
TOTAL DIVIDENDS   (334)   (3,848)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS $ (5,913) $ (3,165) $ (7,565) $ (9,118)
BASIC AND DILUTED LOSS PER COMMON SHARE (IN DOLLARS PER SHARE) | $ / shares [1] $ (1.05) $ (2.29) $ (1.66) $ (8.20)
BASIC AND DILUTED WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING (IN SHARES) | shares [1] 5,655,022 1,382,519 4,554,571 1,111,964
Service revenue, net [Member]        
Revenue, net of contractual allowances and adjustments $ 1,195 $ 899 $ 2,105 $ 1,690
less allowance for doubtful accounts (257) (142) (461) (226)
Net sales 938 757 1,644 1,464
Total cost of sales 770 585 1,445 1,273
Clinical research grants [Member]        
Revenue, net of contractual allowances and adjustments   62   62
Total cost of sales   57   57
Other [Member]        
Revenue, net of contractual allowances and adjustments $ 4 $ (2) $ 11 $ 3
[1] Net loss per share and the number of shares used in the per share calculations for all periods presented reflect the one-for fifteen reverse stock split, which took effect on April 26, 2019.